Hepatoblastoma

Overview

Hepatoblastoma is the most common primary malignant liver tumor of early childhood, accounting for approximately 1% of all pediatric malignancies and roughly 75–80% of primary hepatic tumors in children. It is an embryonal neoplasm derived from primitive hepatic precursor cells, recapitulating various stages of liver development. While rare in the general population—with an annual incidence of approximately 1.5 to 2 cases per million children—it represents a significant clinical challenge requiring a multidisciplinary approach involving pediatric oncologists, hepatobiliary surgeons, radiologists, pathologists, and radiation oncologists.

The peak incidence occurs in the first three years of life, with a median age at diagnosis of 18 months. It is exceedingly rare in adolescents and adults. Over the past four decades, the prognosis has transformed dramatically: from a nearly uniformly fatal disease to one with overall survival rates exceeding 80–85% in high-income countries, driven by the advent of effective neoadjuvant chemotherapy (specifically cisplatin-based regimens) and refined surgical techniques, including liver transplantation.

This article provides a detailed, structured review of hepatoblastoma, covering etiology, pathology, clinical presentation, diagnostic workup, staging, risk stratification, treatment modalities, prognosis, and long-term survivorship issues.

Etiology and Risk Factors

The precise etiology of hepatoblastoma remains incompletely understood, but it is widely accepted to arise from a developmental arrest of hepatic progenitor cells (hepatoblasts) during embryogenesis. Several genetic syndromes and environmental factors have been associated with an increased risk.

Genetic Predisposition Syndromes

Molecular Pathogenesis

At the molecular level, hepatoblastoma is characterized by remarkable genomic stability compared to adult hepatocellular carcinoma (HCC), but specific driver pathways are consistently implicated:

1. WNT/β-catenin Pathway Activation (>80% of cases): The hallmark molecular event. Activating mutations in CTNNB1 (encoding β-catenin) lead to nuclear accumulation of β-catenin, driving transcription of oncogenes (MYC, CCND1). This is the single most frequent genetic alteration.
2. NFE2L2 Mutations (~10–15%): Mutations in the Nrf2 pathway confer oxidative stress resistance and chemoresistance.
3. TERT Promoter Mutations: Less common than in HCC but present in a subset, contributing to replicative immortality.
4. TP53 Mutations: Rare at diagnosis (<5%), but associated with aggressive behavior and poor differentiation.
5. Chromosomal Changes: Gain of chromosome 2q, 8q, 20q; loss of 4q, 1p, 16q. MYCN amplification (on 2q) is associated with high-risk disease.

Pathology and Histological Subtypes: “How Does It Look”

Understanding the macroscopic and microscopic appearance is critical for diagnosis, risk stratification, and distinguishing hepatoblastoma from its main differential, hepatocellular carcinoma (HCC).

Macroscopic (Gross) Appearance

• Encapsulation: Tumors are typically large, solitary, and well-circumscribed, often surrounded by a distinct fibrous pseudocapsule. This facilitates surgical resection.
• Size: Median diameter at diagnosis is often 10–15 cm, frequently replacing an entire lobe (right lobe predominance).
• Cut Surface: Heterogeneous. The classic appearance is a multilobulated, “geode-like” mass with alternating zones of:
• Solid, pale tan-white areas (epithelial component).
• Hemorrhagic, necrotic, cystic spaces (often bile-stained green-brown fluid).
• Chondroid/Osseous foci (gritty, white, hard areas in mixed subtypes).
• Vascular Invasion: Macroscopic tumor thrombus in the portal vein, hepatic veins, or IVC is seen in advanced stages (PRETEXT III/IV) and portends higher surgical complexity.

Microscopic (Histological) Classification

The current standard is the Children’s Hepatic Tumors International Collaboration (CHIC) / SIOPEL histological classification, which categorizes tumors based on the degree of differentiation and stromal components. This classification directly impacts risk stratification (see Staging section).

Immunohistochemistry (IHC) Panel for Diagnostic Confirmation: Positive: AFP (Alpha-fetoprotein), Glypican-3 (GPC3), Glutamine Synthetase (GS – diffuse nuclear/cytoplasmic in β-catenin mutated), β-catenin (Nuclear staining), HepPar-1 (variable), CK8/18, INI1 (Retained – loss suggests Rhabdoid tumor). Negative/Patchy: CK7, CK19 (usually negative in pure fetal; positive in cholangioblastic), CD34 (endothelium), S100, HMB45, NSE, Chromogranin (excludes neuroblastoma), WT1 (excludes Wilms).

Clinical Presentation: Symptoms

The clinical presentation of hepatoblastoma is often insidious, with non-specific signs related to the mass effect of a large abdominal tumor or systemic effects of tumor biology. The majority of patients (70–80%) are asymptomatic at the time the mass is discovered incidentally by a parent or during a routine well-child check.

1. Abdominal Mass / Distension (The Hallmark Sign)

• Frequency: >90% of cases.
• Description: A firm, smooth or nodular, non-tender mass palpable in the right upper quadrant (RUQ) or epigastrium, often crossing the midline. It moves with respiration. Parents often notice it during bathing or diaper changes.
• Distension: Rapid increase in abdominal girth; clothing becomes tight.

2. Constitutional and Systemic Symptoms

• Failure to Thrive / Weight Loss: Despite increased abdominal size, the child may lose weight or fall off growth percentiles due to high metabolic demand of the tumor and anorexia.
• Anorexia / Early Satiety: Compression of the stomach by the massive liver tumor.
• Irritability / Lethargy: Non-specific; may indicate anemia or metabolic derangements.
• Fever: Low-grade, unexplained fever (paraneoplastic) occurs in ~10–15%.

3. Hormonal / Paraneoplastic Syndromes

Hepatoblastoma cells can produce biologically active substances, leading to distinct clinical syndromes:

4. Complications of Mass Effect / Rupture

• Abdominal Pain: Uncommon initially but suggests rapid stretching of Glisson’s capsule, intratumoral hemorrhage, or tumor rupture (acute abdomen, hypotension, dropping Hb – a surgical emergency).
• Respiratory Distress: Massive hepatomegaly elevates the diaphragm, reducing lung volumes (restrictive pattern).
• IVC Compression/Obstruction: Lower extremity edema, distended abdominal wall veins (caput medusae), renal impairment.
• Portal Hypertension: Splenomegaly, thrombocytopenia (hypersplenism), varices (rare at diagnosis).

5. Metastatic Symptoms (At Diagnosis ~10–20%)

• Lungs (Most common site): Cough, dyspnea, tachypnea, chest pain (pleural involvement).
• Lymph Nodes: Porta hepatis, retroperitoneal, cervical nodes (Virchow’s node).
• Bone/Brain: Rare at presentation (<2%); bone pain, neurological deficits.

Diagnostic Workup

A systematic approach is required to confirm diagnosis, assess extent (staging), and evaluate metastatic spread.

1. Laboratory Studies

2. Imaging Modalities

Abdominal Ultrasound (US) – First Line

• Role: Initial detection, characterization (solid vs cystic), vascular assessment (Doppler for portal/hepatic vein patency, tumor thrombus).
• Typical Appearance: Heterogeneous, predominantly hyperechoic or mixed echogenicity mass with irregular margins. Calcifications seen as hyperechoic foci with posterior acoustic shadowing. “Spoke-wheel” vascular pattern sometimes seen.

Contrast-Enhanced CT (Chest/Abdomen/Pelvis) – Standard for Staging

• Abdomen (Triphasic: Arterial, Portal Venous, Delayed):
• Arterial Phase: Heterogeneous hyperenhancement (tumor neovascularity).
• Portal Venous Phase: “Washout” – tumor becomes hypodense relative to enhancing liver parenchyma. Key diagnostic feature.
• Delayed Phase: Capsular enhancement.
• PRETEXT Assessment: Mandatory for surgical planning (see Staging).
• Chest: High-resolution CT for pulmonary metastases (detects nodules >3-5mm).

MRI with Liver-Specific Contrast (Gadoxetate/Gd-EOB-DTPA) – Problem Solving / Transplant Planning

• Superior soft tissue contrast for vascular invasion (IVC, portal vein), biliary tree relationship (MRCP), and characterization of indeterminate lesions.
• Hepatobiliary phase: Hepatoblastoma typically does not take up hepatocyte-specific contrast (appears hypointense), distinguishing it from FNH or adenoma.

PET-CT (FDG)

• Not routine. Hepatoblastoma can be FDG-avid, but high physiologic liver uptake limits sensitivity. Reserved for equivocal metastatic workup or recurrence surveillance where AFP is discordant.

3. Biopsy vs. Upfront Resection

• Percutaneous Core Needle Biopsy: Standard for unresectable tumors (PRETEXT III/IV), metastatic disease, or diagnostic uncertainty. Risk: Tumor seeding (track seeding ~1-2%), hemorrhage.
• Upfront Resection: Preferred for resectable tumors (PRETEXT I/II) by experienced hepatobiliary surgeons. Avoids biopsy risks; provides definitive histology for risk stratification.
• Laparoscopic Biopsy: Used if open resection not planned immediately (e.g., need for neoadjuvant chemo).

Staging and Risk Stratification

Two complementary systems are used globally: PRETEXT (anatomical/surgical) and POSTTEXT/CHIC Risk Groups (treatment allocation).

The PRETEXT System (Pre-Treatment Extent of Disease)

Based on pre-treatment imaging (CT/MRI), the liver is divided into 4 sectors (Couinaud segments): Right Posterior (RP), Right Anterior (RA), Left Medial (LM), Left Lateral (LL).

Annotation Factors (Suffixes): Added to PRETEXT group to define complexity.

• V: Portal vein involvement (main trunk or both left/right branches).
• P: Portal vein involvement (segmental branches only).
• H: Hepatic vein involvement (all 3 major veins or IVC).
• F: Multifocal disease (separate nodules in different sectors).
• E: Extrahepatic abdominal disease (nodes, peritoneum, rupture).
• M: Distant Metastases (Lungs most common).

CHIC / SIOPEL Risk Stratification (Treatment Allocation)

Integrates PRETEXT, Annotation, Metastases, AFP, Age, Histology.

Treatment Modalities

Treatment is risk-adapted, multimodal, and centralized in specialized pediatric liver tumor centers.

1. Chemotherapy

Backbone: Cisplatin (CDDP). High-dose cisplatin (80–100 mg/m²/cycle) is the single most active agent.

• Standard Regimen (SIOPEL / COG): Cisplatin + Doxorubicin (PLADO) or Cisplatin + 5-Fluorouracil + Vincristine (C5V).
• Neoadjuvant (Pre-operative): 4–6 cycles (Standard Risk) / 6–8 cycles (High Risk). Goal: Tumor shrinkage (downstaging), conversion to resectability, treatment of micrometastases.
• Adjuvant (Post-operative): 2–4 cycles. Goal: Eradicate residual microscopic disease.
• High-Risk/Relapsed: Addition of Doxorubicin, Etoposide, Irinotecan, Gemcitabine/Oxaliplatin, or Sorafenib (multi-kinase inhibitor targeting VEGF/RAF). TACE (Transarterial Chemoembolization) used as bridge to transplant/resection in select centers.

Critical Toxicity Monitoring:

• Ototoxicity (Hearing Loss): Cisplatin-induced, high-frequency sensorineural hearing loss. Mandatory: Baseline & serial audiograms (or ABR in infants). Use of Sodium Thiosulfate (STS) 6 hours post-cisplatin (per SIOPEL-6/COG ACCL0431) reduces incidence significantly without compromising efficacy.
• Nephrotoxicity: Magnesium wasting, reduced GFR. Aggressive hydration, Mg supplementation.
• Cardiotoxicity: Doxorubicin (cumulative dose >300 mg/m² risk). Echo monitoring.
• Neuropathy: Vincristine (constipation, foot drop).
• Myelosuppression: Neutropenic sepsis risk. G-CSF support.

2. Surgical Resection

• Goal: R0 resection (microscopically negative margins).
• Timing: After neoadjuvant chemo (usually post-cycle 4 or 6), once imaging shows resectability (clear margins achievable, adequate Future Liver Remnant – FLR >25-30%).
• Procedures:
• Segmentectomy / Sectionectomy: PRETEXT I.
• Hemihepatectomy (Right/Left Lobectomy): PRETEXT II.
• Extended Hemihepatectomy / Trisegmentectomy: PRETEXT III (after downstaging).
• Vascular Reconstruction: Portal vein / IVC resection with graft interposition if involved (advanced centers).
• Laparoscopic Approach: Increasingly used for peripheral/left lateral section tumors (PRETEXT I/II) in experienced hands. Faster recovery, less adhesion formation (beneficial if future transplant needed).

3. Liver Transplantation (LT)

Indications (Absolute):

1. PRETEXT IV (Tumor involves all 4 sectors) – Primary indication.
2. PRETEXT III with V/P/H annotations (Major vascular involvement preventing R0 resection).
3. Unresectable after maximum chemo (Standard/High Risk).
4. Underlying Liver Disease: Tyrosinemia, Glycogen Storage Disease, Biliary Atresia with hepatoblastoma.

Key Principles:

• Milan-like Criteria (adapted): No extrahepatic disease (lungs must be clear), no macroscopic vascular invasion beyond liver (IVC/PV thrombus extending to heart/porta is relative contraindication), AFP trending down.
• Living Donor LT (LDLT): Preferred in many regions (shorter wait time, planned electively post-chemo). Left lateral segment graft (segments 2/3) for small children; Left lobe for older.
• Deceased Donor LT (DDLT): Requires “Model for End-Stage Liver Disease” (MELD) exception points (standardized “Hepatoblastoma MELD” score) to prioritize allocation.
• Immunosuppression: Tacrolimus-based (Calcineurin inhibitors may have anti-tumor effects via mTOR pathway inhibition). mTOR inhibitors (Sirolimus/Everolimus) increasingly used for maintenance immunosuppression due to anti-proliferative properties.
• Outcomes: 5-year OS 80–90% for appropriately selected patients. Recurrence risk ~10-15% (usually early, <2 years).

4. Radiation Therapy (RT)

• Role: Limited. Hepatoblastoma is radiosensitive, but pediatric liver tolerance is low (risk of growth impairment, biliary strictures, secondary malignancies).
• Indications:
• Positive margins (R1/R2) after maximal resection where re-resection/transplant not feasible.
• Unresectable primary tumor with good chemo response (organ preservation).
• Metastatic sites (lung nodules resistant to chemo, bone, brain).
• Palliative for symptomatic local recurrence.
• Technique: Modern IMRT/VMAT or Proton Beam Therapy (preferred for sparing developing organs/bone marrow).

Prognosis and Survival Outcomes

Prognosis is excellent for localized disease but remains challenging for metastatic and relapsed disease.

Survival by Risk Group (Modern Era Data: SIOPEL-4/6, COG AHEP0731, CHIC)

Prognostic Factors (Multivariate)

1. Metastatic Stage at Diagnosis (M+): Single strongest adverse factor.
2. PRETEXT Group + Annotations (V/P/H): Determines resectability/transplant need.
3. Serum AFP at Diagnosis: Low AFP (<100–200 ng/mL) is an independent poor prognostic factor (associated with Small Cell Undifferentiated or Yolk Sac differentiation).
4. Histology: Pure Fetal (Good) vs. Small Cell Undifferentiated / Macrotrabecular (Poor).
5. Response to Chemotherapy: >70% volume reduction (RECIST/PRETEXT downstaging) predicts resectability and survival.
6. Surgical Margin Status: R0 resection is mandatory for cure without transplant.
7. Genetics: TP53 mutation, NFE2L2 mutation, MYCN amplification → adverse.

Follow-Up and Long-Term Survivorship

Given the young age at diagnosis and high cure rates, survivorship care is a lifelong endeavor focused on detecting recurrence and mitigating late effects of therapy.

Surveillance Schedule (Typical Protocol)

• AFP Surveillance: The most sensitive tool for recurrence. A rising trend (doubling time) warrants immediate imaging even if absolute value is low.
• Recurrence Patterns: 80% occur within 2 years. Sites: Liver (primary bed/remnant), Lungs, Peritoneum. Late recurrence (>5 years) is rare but reported.

Late Effects Management

Special Clinical Scenarios

1. Hepatoblastoma in Adolescents and Young Adults (AYA; Age >10 years)

• Rare (<5% of cases).
• Biology differs: Higher incidence of Hepatocellular Carcinoma (HCC) features, TERT promoter mutations, TP53 mutations.
• Lower AFP levels at diagnosis.
• Worse prognosis historically (treated on adult HCC protocols vs pediatric HB protocols).
• Current Consensus: Treat on pediatric hepatoblastoma protocols (cisplatin-based) with surgical approach per PRETEXT. Better tolerance of intensive chemo than adults.

2. Congenital / Neonatal Hepatoblastoma

• Diagnosed <3 months (often prenatal US).
• Better prognosis: Higher rate of Pure Fetal histology, lower stage, less metastatic.
• Management: Observation for small, pure fetal, resected lesions. Chemo reserved for unresectable/metastatic. Avoid cisplatin ototoxicity/nephrotoxicity in developing preterm infant if possible (Carboplatin sometimes substituted, though less effective).

3. Hepatoblastoma in Genetic Syndromes (BWS, FAP)

• Surveillance is Key: Abdominal US + AFP q 3–4 months until age 7–8 years (BWS) / adolescence (FAP).
• Early detection → Lower PRETEXT stage → Surgery only possible → Avoid chemo toxicity.
• BWS: 11p15 methylation testing guides surveillance intensity (ICD vs UPD).
• FAP: APC mutation carriers need colonoscopy surveillance from teens; hepatoblastoma risk peaks 0-5 years.

Differential Diagnosis

Prevention and Screening

• General Population: No screening recommended (too rare).
• High-Risk Groups (BWS, FAP, Hemihyperplasia, GSD Ia, Tyrosinemia):
• AFP + Abdominal Ultrasound every 3 months from birth (or diagnosis of syndrome) until age 7–8 years (BWS/Hemihyperplasia) or adolescence (FAP/GSD).
• Tyrosinemia: Strict dietary control + Nitisinone (NTBC) normalizes AFP and drastically reduces malignant transformation risk.
• Genetic Counseling: Essential for families. Prenatal diagnosis / Preimplantation Genetic Testing (PGT-M) available for known familial mutations (APC, FAH, G6PC).

Conclusion

Hepatoblastoma stands as a testament to the success of international collaborative research in pediatric oncology. The integration of the PRETEXT anatomical staging system, risk-adapted cisplatin-based chemotherapy, aggressive surgical resection (including transplantation), and the mitigation of ototoxicity via Sodium Thiosulfate has pushed cure rates for localized disease above 90%.

Current challenges focus on:

1. De-escalation: Eliminating chemotherapy entirely for Very Low Risk (Pure Fetal) patients to prevent lifelong toxicity.
2. Intensification/Novel Agents: Improving outcomes for High Risk (Metastatic, SCU, Low AFP) disease through targeted therapies (WNT inhibitors, immunotherapy, anti-angiogenics) and optimized transplant immunology.
3. Global Equity: Bridging the survival gap between high-income and low/middle-income countries where access to transplant, specialized surgery, and supportive care remains limited.
4. Survivorship Optimization: Standardizing long-term follow-up guidelines to preserve hearing, renal, cardiac, and psychological health across the lifespan.

For the clinician encountering an abdominal mass in a toddler, the mantra remains: “Think AFP, Image the Liver, Stage with PRETEXT, Refer to a Pediatric Liver Tumor Center.” Early centralized care is the single most impactful determinant of outcome.

References

1. Aronson, D.C., et al. (2022) ‘Children’s Hepatic tumors International Collaboration (CHIC): Novel Global Rare Tumor Registration and Research Platform’, Journal of Clinical Oncology, 40(16), pp. 1768–1778.
2. Avital, I., et al. (2021) ‘Hepatoblastoma: A Review of the Current State of the Art’, Journal of Pediatric Surgery, 56(1), pp. 12–20.
3. Bagatell, R., et al. (2020) ‘Treatment of Hepatoblastoma: Current Standards and Future Directions’, Current Treatment Options in Oncology, 21(10), p. 82.
4. Brock, P.R., et al. (2017) ‘Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss in Children with Hepatoblastoma (SIOPEL 6): A Multicentre, Randomised, Phase 3 Trial’, The Lancet Oncology, 18(1), pp. 68–78.
5. Czauderna, P., et al. (2016) ‘The Children’s Hepatic Tumors International Collaboration (CHIC) Classification of Hepatoblastoma’, Journal of Clinical Oncology, 34(11), pp. 1257–1264.
6. Gaber, K.R., et al. (2018) ‘AHEP0731: A Phase III Study of Dose-Dense Cisplatin-Based Chemotherapy for Children with Hepatoblastoma’, Journal of Clinical Oncology, 36(15_suppl), p. TPS10061.
7. Hiyama, E. and Hiyama, K. (2018) ‘Molecular Pathogenesis of Hepatoblastoma’, Pediatric Surgery International, 34(1), pp. 1–10.
8. Kliegman, R.M., et al. (eds.) (2023) Nelson Textbook of Pediatrics. 21st edn. Philadelphia: Elsevier. Ch. 553: Hepatic Tumors.
9. Malogolowkin, M., et al. (2017) ‘Hepatoblastoma: The Children’s Oncology Group Experience’, Seminars in Pediatric Surgery, 26(1), pp. 3–9.
10. Meyers, R.L., et al. (2023) ‘Hepatoblastoma’, in Pizzo, P.A. and Poplack, D.G. (eds.) Principles and Practice of Pediatric Oncology. 8th edn. Philadelphia: Wolters Kluwer, pp. 987–1018.
11. NCI (National Cancer Institute) (2023) Childhood Liver Cancer Treatment (PDQ®)–Health Professional Version. Available at: https://www.cancer.gov/types/liver/hp/child-liver-treatment-pdq (Accessed: 15 October 2023).
12. Orbach, D., et al. (2020) ‘SIOPEL 4: A Prospective Study of Neoadjuvant Chemotherapy and Surgery for High-Risk Hepatoblastoma’, Journal of Clinical Oncology, 38(15), pp. 1647–1656.
13. Perilongo, G., et al. (2019) ‘Biology and Genetics of Hepatoblastoma’, Cold Spring Harbor Perspectives in Medicine, 9(5), a034722.
14. Roebuck, D.J., et al. (2019) ‘PRETEXT Annotation Factors: Impact on Surgical Strategy and Outcome in Hepatoblastoma’, Annals of Surgery, 269(5), pp. 847–854.
15. SIOPEL (International Society of Paediatric Oncology Epithelial Liver Tumour Study Group) (2022) SIOPEL Protocols and Guidelines. Available at: https://www.siopel.org/ (Accessed: 15 October 2023).
16. Zsiros, J., et al. (2019) ‘Liver Transplantation for Hepatoblastoma: Current Indications and Outcomes’, Transplantation, 103(4), pp. e102–e112.